Capricor Therapeutics Inc CAPR:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/03/21 EST
5.72quote price arrow down-0.02 (-0.35%)
Volume
441,837
52 week range
0.88 - 12.32

...

Loading . . .

KEY STATS

  • Open5.79
  • Day High5.89
  • Day Low5.51
  • Prev Close5.72
  • 52 Week High12.32
  • 52 Week High Date07/28/20
  • 52 Week Low0.88
  • 52 Week Low Date03/12/20
  • Market Cap116.97M
  • Shares Out20.45M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta6.66
  • 1 Year % Change401.75

RATIOS/PROFITABILITY

  • EPS (TTM)-1.07
  • P/E (TTM)-5.35
  • Fwd P/E (NTM)-28.60
  • EBITDA (MRQ)-9.748M
  • ROE (MRQ)-64.44%
  • Revenue (MRQ)470,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-2,307.33%
  • Debt To Equity (MRQ)12.15%

EVENTS

  • Earnings Date03/16/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Capricor Therapeutics Inc News

Latest CAPR News From Our Partners

QUOTE FINDER

Profile

MORE
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in...
Frank Litvack M.D.
Chairman
Linda Marban Ph.D.
President
Anthony Bergmann
Chief Financial Officer
Karen Krasney J.D.
Executive Vice President
Thomas Copmann Ph.D.
Vice President
Address
8840 Wilshire Blvd Fl 2
Beverly Hills, CA
90211-2606
United States